Study of Vimseltinib for Tenosynovial Giant Cell Tumor (NCT05059262)
A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor (MOTION)
🩺 Plain-English Summary (8th-Grade Level)
This is a multicenter Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT) in cases where surgical removal of the tumor is not an option. The study consists of two parts. In Part 1, eligible study participants will be assigned to receive either vimseltinib or matching placebo for 24 weeks. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. MRI scans will be used to evaluate the response of the tumors to the treatment. Participants assigned to placebo in Part 1 will have the option to receive vimseltinib for Part 2. Part 2 is a long-term treatment phase in which all participants receive open-label vimseltinib.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (35 Sites)
Showing the first 25 of 35 sites.
- City of Hope — Duarte, California
- UC Davis Comprehensive Cancer Center — Sacramento, California
- University of Colorado — Aurora, Colorado
- University of Kansas — Kansas City, Kansas
- Dana Farber Cancer Institute — Boston, Massachusetts
- Mayo Clinic Rochester — Rochester, Minnesota
- Memorial Sloan-Kettering Cancer Center — New York, New York
- Duke Sarcoma Research — Durham, North Carolina
- Ohio State University — Columbus, Ohio
- University of Texas MD Anderson Cancer Center — Houston, Texas
- Seattle Cancer Care Alliance — Seattle, Washington
- Chris O'Brien Lifehouse — Camperdown,
- McGill University — Montreal,
- Princess Margaret Hospital — Toronto,
- Institut Bergonié — Bordeaux,
- Centre Léon Bérard — Lyon,
- Institut Gustave Roussy — Villejuif,
- Helios Klinikum Berlin-Buch — Berlin,
- University Hospital Essen (Universitätsklinikum Essen) — Essen,
- Prince of Wales Hospital — Hong Kong,
- Istituto Ortopedico Rizzoli — Bologna,
- Fondazione IRCCS Istituto Nazionale dei Tumori — Milan,
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" — Naples,
- Istituto Oncologico Veneto — Padua,
- Istituto Nazionale Tumori Regina Elena — Rome,
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Tenosynovial Giant Cell Tumor
- Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) — Beverly Hills, California
- MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib — Wilmington, North Carolina
Explore by condition: All Tenosynovial Giant Cell Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.